

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
A36	4,992,419	2/12/91	Woog et al.	
A37	5,824,672	10/20/98	Simpkins et al.	
A38	6,242,570	6/05/01	Sytkowski	
A39	6,340,742	1/22/02	Burg et al.	
A40	6,521,245	2/18/03	Zaharia	
A41	6,531,121	3/11/03	Brines et al.	
A42	6,583,272	6/24/03	Bailon	
A43	6,673,575	01/06/04	Franze	
A44	7,214,532	5/08/07	Stern et al.	
A45	7,309,687	12/18/07	Brines et al.	
A46	7,345,019	03/18/08	Brines et al.	
A47	2002/0031806	3/14/02	Lee	
A48	2002/0052309	5/02/02	Anagnostou et al.	
A49	2002/0061849	5/23/02	Nielsen et al.	
A50	2002/0077294	6/20/02	Kay et al.	
A51	2002/0081734	6/27/02	Choi et al.	
A52	2002/0086816	7/04/02	Brines et al.	
A53	2003/0077753	4/24/03	Tischer	
A54	2003/0083251	5/01/03	Westenfelder	
A55	2003/0104988	6/5/03	Brines	
A56	2003/0113871	6/19/03	Lee et al.	
A57	2003/0120045	6/26/03	Bailon	
A58	2003/0124115	7/3/03	Lee et al.	
A59	2003/0134798	7/17/03	Brines et al.	
A60	2003/0166566	9/04/03	Kinstler et al.	
A61	2004/0009902	1/15/04	Boime	
A62	2004/0018978	1/29/04	Campana et al.	
A63	2004/0091961	5/13/04	Evans et al.	

EXAMINER

NYI-4081908v2

/Aditi Dutt/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A64	2004/0096447	5/20/04	Yasuda et al.	
	A65	2004/0209812	10/21/04	Farrell et al.	
	A66	2004/0214236	10/28/04	Brines et al.	
	A67	2005/0176627	08/11/05	Cerami et al.	
	A68	2006/0034799	2/16/06	Brines et al.	
	A69	2006/0216757	9/28/06	Brines et al.	
	A70	2007/0129293	6/07/07	Coleman et al.	
	A71	2007/0298031	12/27/07	Brines et al.	
	A72	2008/0045412	02/21/08	Brines et al.	
	A73	09/547,220	4/11/00	Brines et al.	
	A74	09/716,960	11/21/00	Brines et al.	
	A75	09/716,963	11/21/00	Brines et al.	
	A76	09/718,829	11/21/00	Brines et al.	
	A77	10/554,517	10/25/05	Brines et al.	
	A78	11/283,024	11/18/05	Cerami et al.	
	A79	11/631,458	1/03/07	Cerami et al.	
	A80	11/880,275	7/19/07	Brines et al.	
	A81	12/123,828	5/20/08	Brines et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL*		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B09	DE 198 57 609 (with translation)	6/15/00	Ehrenreich and Gleiter		
	B10	EP 0640619	8/16/94	Amgen Inc.		
	B11	EP 0668 351	8/23/95	Amgen, Inc.		
	B12	EP 1064951	6/28/00	F. Hoffmann-La Roche AG		
	B13	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		
	B14	WO 86/03520	6/19/86	Genetics Institute, Inc.		

EXAMINER
NYI-4081908v2

/Aditi Dutt/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL*	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B15 WO 91/05867	5/02/91	Amgen Inc.		
	B16 WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B17 WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B18 WO 96/14081	5/17/96	Boehringer Mannheim GMBH		
	B19 WO 97/08307	3/6/97	II Dong Pharmaceutical Co Ltd.		
	B20 WO 98/10650	3/19/98	East Carolina University		
	B21 WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		
	B22 WO 00/24893	5/4/00	Amgen, Inc.		
	B23 WO 00/032772	6/8/00	Eli Lilly & Co.		
	B24 WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		
	B25 WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		
	B26 WO 01/81405	1/11/01	Amgen Inc.		
	B27 WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		
	B28 WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		
	B29 WO 02/14356	2/21/02	Althoff, Claudia		
	B30 WO 02/053580	7/11/02	Kenneth S. Warren Laboratories		
	B31 WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
	B32 WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B33 WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
	B34 WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
	B35 WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
	B36 WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B37 WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
	B38 WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
	B39 WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
	B40 WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B41 WO 06/002646	1/12/06	Lundbeck A/S		

EXAMINER
NYI-4081908v2

/Aditi Dutt/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL*	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
B42	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		
B43	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
C123	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper I, Declaration, Brines clean copy of claims, and Ehrenreich clean copy of claims (10/02/06)	
C124	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
C125	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant alpha-crystallins," Current Eye Research, Vol. 18:270-276	
C126	ALI et al., 1995, "Identification of the tryptophan residue in the thiamin pyrophosphate binding site of mammalian pyruvate dehydrogenase," J Biol. Chem., Vol 270(9):4570-4	
C127	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits," Pediatric Res., Vol. 9:131-387	
C128	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol. Cell. Biol. 14(10):6506-6514 Barber et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol. Cell. Biol. 14(10):6506-6514	
C129	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," J. Biol. Chem. 272(8):4985-4992	
C130	BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
C131	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res. Commun. 164(2):788-795	
C132	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
C133	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
C134	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase C-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
C135	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury," Proc Natl Acad Sci USA, Vol. 97(19):10526-31	
C136	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
C137	BUEMI et al., 2000, "Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal	

EXAMINER
NYI-4081908v2

/Aditi Dut/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	fluid erythropoietin concentration," Nephrol. Dial. Transplant. Vol. 15:422-423	
C138	BUEMI et al., 2002, "Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
C139	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24(3):394-401	
C140	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
C141	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Brain Res Mol Brain Res, Vol. 81, pp. 29-42	
C142	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35	
C143	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
C144	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960	
C145	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687	
C146	DEL CAYRE et al., 1992, "Aortic perfusion pressure as early determinant of beta-isomyosin expression in perfused hearts," Amer. J. Physiol., Vol. 263(5 Pt 2):H1537-45	
C147	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
C148	DENIZOT et al., 1986, "Rapid colorimetric assay for cell growth and survival - Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immunol. Methods, Vol. 89:271-277	
C149	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
C150	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
C151	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
C152	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
C153	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The Institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
C154	FDA Alert (16 November 2006, updated 16 February 2007 and 9 March 2007), http://www.FDA.gov/cder/drug/infosheets/hcp/rhe2007.hcp.html	
C155	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78, pp. 753-756	
C156	FRANK, 2002, "Receptor dimerization in GH and erythropoietin action--it takes two to tango, but how?" Endocrinology 143(1):2-10	
C157	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
C158	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Leukemia, 11 Supl 3, pp. 444-5	

EXAMINER
NVI-4081908v2

/Aditi Dutt/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
C159	GAO et al., 1994, "Determination of the effective charge of a protein in solution by capillary electrophoresis," Proc Natl Acad Sci USA, Vol. 91(25):12027-30		
C160	GLOMB et al., 1995, "Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction," J. Biol Chem. Vol. 270(17):10017-26		
C161	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer. Chem Soc., Vol. 124:544-555		
C162	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration," Nature Medicine, Vol. 8, pp. 718-724		
C163	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta. 1592(3):215-223		
C164	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells," Toxicological Sciences, Vol. 64:83-89		
C165	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the b chain of the GM-CSF receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066		
C166	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b		
C167	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in Escherichia coli," J. Biol. Chem. 267(21):15205-15209		
C168	HERMENTIN et al., 1996, "The hypothetical N-glycan charge: a number that characterizes protein glycosylation," Glycobiology Vol. 6(2):217-30		
C169	HOKKE et al., 1995, "Structural analysis of the sialylated N- and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetylglucosamine units," Eur. J. Biochem., Vol. 228(3):981-1008		
C170	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357		
C171	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients," Nephron, Vol. 72, pp. 30-36		
C172	ITO H et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327		
C173	JACOBS K et al., 1985, "Isolation and characterization of genomic and cDNA clones of human erythropoietin," Nature 313(6005):806-810		
C174	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677		
C175	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35		
C176	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site," Chem Biol Interact. 119-120: 79-84		
C177	JUBINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773		
C178	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the		

EXAMINER
NYI-4081908v2

/Aditi Dutt/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	erythropoietin receptor," Blood 90(5):1867-1873	
C179	JUUL, 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage," Acta Paediatr. Suppl. Vol. 438, pp. 36-42	
C180	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin," Glycobiology, Vol. 11(12):1043-1049	
C181	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation," Blood 99(1):102-110	
C182	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," Blood, Vol. 73, pp. 375-80	
C183	KOKKINI et al., 1980, "Modification of hemoglobin by ninhydrin," Blood, Vol. 56(4):701-705	
C184	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
C185	KROHN et al., 1998, "Staurosporine-induced apoptosis of cultured rat hippocampal neurons involves caspase-1-like proteases as upstream initiators and increased production of superoxide as a main downstream effector," J Neurosci. Vol. 18(20):8186-8197	
C186	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes," Proc. Natl. Acad. Sci. USA 93(1):231-235	
C187	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242	
C188	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain," J. Biol. Chem. 272:32395-32400	
C189	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc," Mol. Cell. Biol. 14(10):6926-6935	
C190	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
C191	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
C192	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
C193	MAKITA et al., 1992, "Immunochemical detection of advanced glycosylation end products in vivo," J. Biol. Chem., Vol. 267:5133-5138	
C194	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells," J Biol Chem., Vol. 268:11208-11216	
C195	MENNINI et al., 2006, "Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo," Mol Med., Vol. 12(7-8):153-160	
C196	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18(1):13-17	
C197	MURRAY, 1996, Harpers Illustrated Biochemistry 26 th ed. pp. 524-526, McGraw-Hill Co..	
C198	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
C199	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-33	

EXAMINER
NYI-4081908v2

/Aditi Dutt/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with AIPPE 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
C200	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoietin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
C201	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethane," J. Biol. Chem. Vol. 260(12):7316-21	
C202	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	
C203	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.	
C204	PATTHY et al., 1975, "Identification of functional arginine residues in ribonuclease A and lysozyme," J. Biol. Chem. Vol. 250(2):565-9	
C205	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-5	
C206	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980	
C207	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	
C208	PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769	
C209	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J Biol Chem., Vol. 246:939-845	
C210	RABUFFETTI et al., 2000, "Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines," J Neurosci., Vol. 20:4398-4404	
C211	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
C212	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
C213	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurointricarboxylic acid," Vis. Res. 37:3445-51	
C214	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHu-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2(3):97-100	
C215	SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift für Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only)	
C216	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
C217	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
C218	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
C219	SIREN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98:4044-4049	
C220	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	

EXAMINER
NYI-4081908v2

/Aditi Dutt/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-022-999

APPLICATION NO.

10/612,665

APPLICANT

Nielsen et al.

FILING DATE

July 1, 2003

ART UNIT

1649

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C221	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C222	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535	
	C223	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402	
	C224	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C225	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448	
	C226	TSUDA et al., 1990, "The role of carbohydrate in recombinant human erythropoietin," Eur. J. Biochem. Vol. 188:405-411	
	C227	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medica, Vol. 31(11):505-514 (Abstract only)	
	C228	VANSTEENKISTE et al., 2003, "Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C229	VILLA et al., 2003, "Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis," J. Exp. Med., Vol. 198(6):971-975	
	C230	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29:8509-8517	
	C231	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
	C232	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p," Blood 76(1):24-30	
	C233	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C234	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18(1):129-38	
	C235	YET et al., 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C236	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C237	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction," Oncologist 1(5):337-339	
	C238	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C239	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	

EXAMINER
NYI-4081908v2

/Aditi Dut/

DATE CONSIDERED

12/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.D./